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Effect of vaiproate on renal metabolism In the intact dog. Vaiproate is
an antiepileptic drug known to induce hyperammonemia in humans.
This hyperammonemia might result from a reduced detoxification of
ammonium in the liver and/or from an accelerated renal ammoniagene-
sis. Six dogs with normal acid-base equilibrium and eight dogs with
chronic metabolic acidosis were infused with valproate directly into
their left renal artery in order to obtain arterial concentrations around 3
to 4 mM. The arterial ammonium concentration rose only in chronically
acidotic dogs, whereas the lactate concentration and the lactate/pyru-
vate ratio increased in both groups. The urinary excretion of lactate and
pyruvate increased markedly but the urinary excretion of other relevant
metabolites remained minimal. Renal glutamine utilization and ammo-
nium production were not changed by valproate administration in
normal dogs but increased modestly in acidotic dogs. However, renal
lactate utilization was drastically reduced and in fact, changed into a net
production of lactate. Valproate strikingly reduced the renal cortical
concentrations of glutamine, glutamate, aiphaketoglutarate and citrate,
and more modestly those of malate, oxaloacetate, aspartate, alanine
and ATP. By contrast, the tissue lactate concentration and the lactate/
pyruvate ratio were markedly increased. In experiments with brush
border membrane vesicles, valproate inhibited the lactate transporter.
These results suggest that high concentrations of valproate drastically
inhibited the proximal reabsorption and the proximal and distal oxida-
tion of lactate and pyruvate. Valproate probably became itself a
significant energetic substrate for the kidney.
Vaiproate or dipropylacetate, an eight-carbon branched chain
fatty acid, is a widely used antiepileptic drug [1]. Acute [2, 3]
and chronic [3—61 hyperammonemia have been reported with its
use, possibly due to a reduced rate of ammonium detoxification
through urea synthesis in the liver [7, 8], and/or accelerated
renal glutamine uptake and ammoniagenesis [9, 10]. The first
mechanism was demonstrated in isolated rat liver mitochon-
dna, where valproate inhibited hepatic ureagenesis through
depression of mitochondrial synthesis of N-acetylglutamate
[11]. The second mechanism is also possibly involved, since
intravenous vaiproate accelerated renal glutamine utilization
[10] and increased ammonium release into the renal vein in both
man [9, 10] and the rat [12]. Recent in vitro studies have shown
that valproate accelerates glutamine utilization and ammonia-
genesis in rat [13] and dog [14] renal cortical tubules.
The present study was undertaken to evaluate the potential
effects of vaiproate on renal ammoniagenesis in the intact dog
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and to determine the sites and mechanisms of the various
effects of valproate on renal metabolism. For this purpose, the
renal utilization or production and the renal cortical concentra-
tions of relevant metabolites were assessed in dogs with normal
acid-base equilibrium and chronic metabolic acidosis before
and after valproate administration.
Our data demonstrate that vaiproate does not change renal
glutamine utilization and ammonium production in normal
dogs, but modestly increases these parameters in chronically
acidotic dogs. Furthermore, valproate strikingly increases the
urinary excretion of lactate and pyruvate and markedly inhibits
the oxidation of these substrates by the kidney.
Methods
Fourteen studies were carried out on six normal (18 to 42 kg)
and eight chronically acidotic (17 to 23 kg) mongrel dogs.
Chronic metabolic acidosis was induced by the daily adminis-
tration of ammonium chloride (10 g/day) for at least five days.
After an overnight fast, each dog was anesthetized with intra-
venous sodium pentobarbital (30 mg/kg of body weight) and
received additional small doses whenever necessary during the
experiments. A Harvard respirator was used to ventilate the
dogs mechanically through a cuffed endotracheal tube. The rate
and depth of respiration were initially adjusted to maintain
arterial carbon dioxide tension (PCO2) around 35 mm Hg. No
further attempts were made to prevent arterial PCO2 variations
during the remainder of the experiments.
After a priming dose of creatinine (20 mg/kg of body weight),
a 5% mannitol solution containing 2 g of creatinine and 1 g of
p-aminohippurate (PAH) per liter was adjusted to pH 7.0, and
infused into a jugular vein at a constant rate of 2 mI/mm. The
abdominal cavity was opened through a midline incision and the
left renal vein was catheterized under direct inspection after
ligation of the left ovarian or spermatic vein. An isotonic saline
solution was infused slowly through the catheter inserted into
the left renal vein. During the surgical procedure, each dog
received 300 ml of isotonic saline. The left ureter was also
catheterized and urine was collected under mineral oil. After
careful dissection of the renal pedicle to make sure that only
one artery supplied the left kidney, an isotonic saline solution
was infused at a rate of 0.25 ml/min through a curved 25-G
needle inserted into the left renal artery. If branching of the
renal artery was observed, the site of infusion was well before
that of branching, During the experiment, blood was drawn
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anaerobically through a femoral artery catheter and analyzed
immediately for acid-base parameters.
A tissue sample of the right kidney cortex was obtained and
instantaneously freeze-clamped between two aluminum blocks
cooled to the temperature of liquid nitrogen according to the
technique of Wollenberger, Ristau and Schoffa [151. The inter-
val between removal of a portion of the superficial renal cortex
and the freeze-clamping procedure was always less than 5
seconds. The right renal pedicle was ligated immediately after
this procedure and the left kidney was studied. Following a
30-minute equilibration period, renal ammoniagenesis and the
renal utilization or production of glutamine, glutamate, alpha-
ketoglutarate, aspartate, alanine, lactate, pyruvate and citrate
by the left kidney were measured by three determinations of
arteriovenous differences, and four consecutive, 10-minute
urine collections. We have previously shown that unilateral
nephrectomy per se does not change renal metabolism and renal
metabolite profile 90 minutes after unilateral nephrectomy [161.
Dogs with normal acid-base equilibrium
In the first series of experiments, six dogs were infused
directly into their left renal artery for 120 minutes with a half
molar solution of sodium valproate, prepared in a normal saline
solution by neutralizing valproic acid with sodium hydroxide to
pH 7.4. The rate of infusion of valproate was increased from 1
mg/kg/mm during the first 30 minutes to 2 mg/kg/mm during the
second 30 minutes, to 4 mg/kg/mm during the third 30 minutes,
and finally to 8 mg/kg/mm during the last 30 minutes of infusion
(a total cumulative dosage of 450 mg/kg). During the infusion of
valproate, twelve consecutive, 10-minute urine collections
bracketed by nine determinations of arteriovenous differences
were obtained. As soon as the last blood sample had been
drawn, that is, after 120 minutes of vaiproate administration, a
tissue sample from the remaining left kidney was freeze-
clamped as described above and the animal was sacrificed. The
renal cortical metabolites were thus determined before and after
120 minutes of valproate administration.
Dogs with chronic metabolic acidosis
In the second series of experiments, eight dogs were infused
with the same solution of sodium vaiproate at a dose of 4
mg/kg/mm directly into their left renal artery for 70 minutes.
After a 10-minute equilibration period, six consecutive, 10-
minute urine collections bracketed by four determinations of
arteriovenous differences were obtained. After 70 minutes of
vaiproate administration, a tissue sample from the remaining
left kidney was freeze-clamped.
Transport studies
In order to elucidate the origin of the lactaturia induced by
valproate, brush border membrane vesicles were prepared from
dog kidney cortex by calcium precipitation according to the
technique of Evers et al [171. These vesicles were used to study
the effect of valproate on L-lactate transport. The uptake of
'4C[UJ-L-lactate (40 M) by freshly prepared vesicles sus-
pended in 50 mt Tris-HEPES buffer was studied under condi-
tion of sodium (150 m out, 0 in) and H (pH 6 out, pH 8 in)
gradients in absence or in presence of valproate (0, 0.1, 1 and 5
mM), acetate (5 mM) or 5-hydroxy-cyano-cinnamate (5 mM),
Two types of experiments were performed: in the first type, the
vesicles were exposed to '4C-lactate for 15, 30, 60, 120, 300, 600
and 3600 seconds, filtered, and were washed with 8 ml sodium-
free buffer (pH 6). In the second type of experiments, the
transport was studied at a fixed time (30 see) while the concen-
tration of valproate, acetate, and cinnamate was varied from 0.1
to 10 mM. At the end of the incubation, the vesicles were diluted
in 1 ml of an ice-cold lactate-free, sodium-free and pH 6.0
solution, and rapidly filtered on 0.45 mesh Amicon filters
(Amicon Corp., Lexington, Massachusetts, USA). The filters
were then washed with 8 ml of the same solution, dissolved in
Filter CountTM (Packard Instruments, Downers Grove, Illinois,
USA) scintillation cocktail overnight and counted.
Analytical methods
The pH of blood and urine and the arterial and renal venous
blood P02 were measured anaerobically at 38°C with a digital
acid-base analyzer (Radiometer, model PHM 72, Copenhagen,
Denmark). Analytical methods used to determine carbon diox-
ide content, sodium, potassium, chloride, phosphate, creati-
nine, and PAH concentrations have been described previously
[18, 19]. The plasma valproate concentration was measured by
the homogeneous enzyme immunoassay technique of Elyas et
al [201. The frozen tissues were pulverized and extracted with
four volumes 10% of wt/vol perchloric acid per gram of tissue.
Concentration of metabolites was measured on a neutralized
extract of deproteinized blood, urine or tissue by methods
previously described [161.
Calculations
Plasma carbon dioxide tension and bicarbonate concentration
were calculated from the Henderson-Hasselbaich equation us-
ing a solubility coefficient of 0.0301 and a pK' of 6.10 for
carbonic acid. For urine, a solubility coefficient of 0.0309 was
used while the pK' was 6.33 — 0.5 VNa) + (K), the
concentrations of Na and K being expressed in equivalents per
liter [21]. Blood oxygen content was calculated from the P02,
pH, pCO2, body temperature, hemoglobin and hematocrit as
described by Kelman [22]. Exogenous creatinine clearance was
used to estimate glomerular filtration rate (GFR). Renal blood
flow was calculated from the PAH clearance (corrected for
renal extraction) and the hematocrit value. Renal utilization or
production of each metabolite took into account the net urinary
losses according to the Wolf's equation as modified by Cohen
[23] for substances utilized or produced by the kidney. Renal
cortical oxaloacetate concentration was calculated by two
independent methods based on the assumption that the lactate
dehydrogenase, malate dehydrogenase, and aspartate amino-
transferase systems are in near equilibrium in the dog kidney
cortex [24]. Renal cortical ammonium concentration was calcu-
lated from the renal vein ammonium concentration [25]. In
order to express the renal utilization or production of metabo-
lites at comparable rates of sodium filtration and reabsorption,
these parameters were also expressed per 100 ml GFR. The
rationale of this calculation was fully explained in a recent
publication [26].
Statistical analysis
Unless otherwise specified, the term significant is used
throughout the paper to describe a difference with a P value of
less than 0.05. A two-way variance analysis for repeated
Rengel-Aranda et a!: Vaiproate and renal metabolism 647
Table 1. Effect of progressive infusion of valproate in dogs with normal acid-base equilibrium
Control
Valproate
I mg/kg/mm 2 mg/kg/mm 4 mg/kg/mm 8 mg/kg/mm
Arterial blood
Valproate mi 0 0.60 0.osa 1.38 0.07 3.04 o.loa 6.28 0.28a
Ammonium miu 0.07 0.01 0.06 0.01 0.07 0.01 0.08 0.01 0.08 0.02
Glutamine (plasma) mw 0.44 0.04 0.34 0.02a 0.32 0.02 0.31 0.03a 0.31 o.03
Lactate msi 1.50 0.24 1.74 0.33 2.05 0.41 2.34 0.44a 2.74 o.Soa
Pyruvate mM 0.09 0.01 0.08 0.004 0.06 0.01 0.05 0.0l 0.04 0.Ola
Lactate/pyruvate 17 22 34 47 69
Urine
pH 7.04 0.21 7.20 0.11 7.18 0.12 7.25 0.11 7.36 0.07
CHC03/GFR % 2.4 0.5
C lactate/GFR % 0.7 0.2
4.3 0.6
3.8 0.8
4.3 0.5
18.6 1.sa
7.0 l.0
42.7 57a
13.4 l.3
81.5 6.9a
C pyruvate/GFR % 1.6 0.5 4.9 0.7 19.3 3.0 61.8 l1.Oa 152.1 l7.2a
GFR mI/mm 34.4 8.0 32.2 7.8 33.3 7.8 29.2 6.7 22.9 5.6k
Renal blood flow ml/min 253 25 202 29 185 43 185 58 165 62
Renal utilization or production of metabolites
Total ammonia production 87 20 87 14 83 8 87 8 99 11
Glutamine utilization —68 20 —72 16 —60 7 —65 6 —69 11
Lactate utilization
—204 58 —106 38 —27 l4 —21 3l 18 44
Pyruvate production 19 13 8 8 13 5 14 3 15 5
Citrate utilization —18 5 —15 4 —15 4 —10 2 —11 2
Values are means SE (N = 6 dogs) and were calculated from the means of three (during the control period) and two (during the experimental pe-
riods) arterial blood values, from the means of four (during the control period) and three (during the experimental periods) 10-mm urinary
collections or renal utilizations or productions of metabolites in micromoles per 100 ml GFR.
Significant difference from the mean control value, P < 0.05
measurements on one level was performed, followed by a
comparison of all mean values obtained by the Newman-Keuls
procedure [271. When specified, some comparisons were also
made using Student's t-test for paired or unpaired data.
Results
Dose-response study of valproate in dogs with normal
acid-base equilibrium
The effects of the infusion of progressive quantities of valpro-
ate in dogs with normal acid-base equilibrium are depicted in
Table 1. Despite the progressive rise in the arterial plasma
vaiproate concentration to values exceeding 6 mM, the arterial
ammonium concentration was not significantly increased nor
were there significant changes in blood acid-base parameters
and plasma electrolytes. Valproate decreased the arterial
plasma concentrations of glutamine and citrate, but did not
significantly alter the concentrations of glutamate, aiphaketo-
glutarate, aspartate and alanine. A stepwise increment in lactate
concentration (reflecting either a decreased lactate utilization or
an accelerated production) was observed in parallel with
valproate infusion. Because lactate increased in the presence of
a decreased pyruvate concentration, the arterial lactate/pyru-
vate ratio rose progressively and markedly, reflecting a NAD/
NADH change in undefined organs.
Valproate administration did not induce a significant bicar-
bonaturia since the fractional bicarbonate excretion did not
exceed 13% with the highest dose of valproate. This can be
accounted for in part by the modest volume expansion caused
by the infusion of isotonic saline into the left renal vein. This
expansion could also account, at least in part, for the modest
rise in urine flow and the fractional excretion of sodium,
potassium and chloride observed during vaiproate infusion.
Fractional phosphate excretion remained around 20% before
and during vaiproate infusion. The urinary fractional excretion
of glutamine, glutamate, alphaketoglutarate and citrate re-
mained minimal before and during valproate infusion. Howev-
er, a marked rise in the urinary excretion of lactate (Fig. 1) and
pyruvate (the amount excreted into the urine exceeding the
filtered pyruvate with the highest dose of valproate) indicates an
inhibition of the reabsorption of these organic anions, presum-
ably in the proximal tubule. At plasma valproate concentrations
not exceeding 3 mrvi, no significant renal hemodynamic effects
were observed.
Valproate infusion did not significantly modify the production
_______________ Vaiproate ________________
mg/kg/rn/n
40
30'
c' •
C.)
10
0
Fig. 1. Urinary lactate excretion observed before and during the
infusion of progressive quantities of valproate in dogs with normal
acid-base equilibrium.
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Table 2. Effect of valproate on arterial blood parameters
Normal dogs Acidotic dogs
control valproate control vaiproate
Valproate m 0 3.04 0.10 0 4.66 0.64a
pH 7.38 0.01 7.39 0.02 7.08 0.07k' 7.08 0.04
PCO2 mm Hg 32.2 3.0 34.2 2.8 35.0 0.5 34.3 0.8
Bicarbonate miii 18.2 1.5 19.9 1.7 10.8 i.i' 10.5 1.0
P02, mm Hg NM NM 105.0 1.9 119.2 4.3
Sodium mst 143.9 2.5 147,7 2.5 143.7 0.4 147.1 2.5k
Potassium m 3.4 0.1 3.6 0.3 2.8 + 003b 3.1 0.4
Chloride m 106.3 1.9 109.1 1.6 124.9 11b 124.6 1.2
Ammonium m 0.07 0.01 0.08 0.01 0.11 0.O1' 0.16 o.ola
Glutamine (plasma) m 0.44 0.04 0.31 0,03a 0.46 0.05 0.43 0.05
Glutamate (plasma) m 0.04 0.01 0.03 0.01 0.02 0.004 0.02 0.003
Alanine msi 0.24 0.02 0.20 0.02 0.55 006b 0.43 0.04
Lactate mi 1.50 0.24 2.34 O,44a 1.08 0.20 2.34 0.26a
Pyruvate mw 0.09 0.01 0.05 0.01 0.10 0.01" 0.04 0.Ola
Lactate/pyruvate 17 47 11 59Citrate m 0.11 0.02 0.09 0.02 0.06 0.01 0.05 0.01
Values are means SE (N = 6 normal dogs and 8 acidotic dogs) and were calculated from the means of three (during the control period) and two
(during the experimental periods) blood values. The values presented during valproate infusion were observed when a dose of 4 mg/kg/mm was
infused in both groups of dogs. NM, not measured.
a Significant difference (P < 0.05) from the mean control value, the comparisons being made with the Student's i-test for paired data.b Significant difference (P < 0.05) between the control values in normal and acidotic dogs, the comparisons being made with the Student's i-test
for unpaired data.
of ammonium nor the utilization of glutamine by the kidney, as
both metabolic events occur mostly in the proximal tubules of
normal dogs. The ratio of ammonium production to glutamine
utilization remained around 1.4, and vaiproate did not alter the
distribution of the ammonium produced between the urinary
compartment and the renal venous blood. The renal production
of glutamate and alanine did not change significantly and that of
aiphaketoglutarate and aspartate remained minimal. By con-
trast, vaiproate markedly decreased lactate utilization in both
the proximal and distal tubules of the dogs with normal acid-
base equilibrium. This dose-dependent reduction in lactate
utilization was not accompanied by a decreased reabsorption of
sodium and chloride. This suggests that a new substrate was
now metabolized in the proximal tubules as well as in the more
distal thick ascending limb of Henle to support the cellular
work, despite the absence of lactate oxidation.
Comparative effects of valproate in normal and chronically
acidotic dogs
Arterial blood parameters. In chronically acidotic dogs, the
ATP turnover is mainly supported by glutamine in the proximal
tubule and by lactate in the distal nephron 128, 29], thus
allowing a clear distinction between proximal and distal meta-
bolic effects. For this reason, we decided to compare the renal
effects of 3 to 4 mi arterial valproate in normal and acidotic
dogs (Table 2). In the control periods, all the effects that were
expected with ammonium chloride acidosis were observed in
the acidotic dogs; that is lower arterial pH, lower plasma
bicarbonate and potassium concentrations, and a higher plasma
chloride concentration. Valproate administration had compara-
ble effects in both normal and acidotic dogs on the arterial con-
centration of lactate and pyruvate and on the arterial lactate!
pyruvate ratio. A significant valproate-induced rise in arterial
ammonium concentration occurred only in chronically acidotic
animals, suggesting that, in the dog, valproate produces sys-
temic hyperammonemia only when a greater load of ammoni-
urn, due to an accelerated release into the renal vein, must be
detoxified by the liver.
Urinary parameters. A modest rise in urine flow and frac-
tional excretion of sodium and chloride was observed in both
groups of dogs during valproate infusion (Table 3). The urinary
excretion of lactate and pyruvate increased markedly in all
instances. A 3 to 5 mvt valproate concentration had no signifi-
cant effects on renal hemodynamics in the normal dogs, but
decreased the glomerular filtration rate and renal blood flow in
chronically acidotic dogs.
Renal utilization or production of metabolites. As expected,
chronic metabolic acidosis increased renal ammonium produc-
tion (Table 4). Valproate infusion did not change the release of
ammonium into the renal vein nor alter ammonium urinary
excretion in normal dogs; however, it increased the urinary
excretion of ammonium in the chronically acidotic dogs signif-
icantly. The total ammonium production and the renal utiliza-
tion of glutamine increased modestly in acidotic dogs. The rise
in urinary ammonium excretion could not be accounted for by
changes in urine flow or pH, but possibly could result from the
presence of increased amounts of poorly reabsorbable anions
(lactate, pyruvate, vaiproate, metabolites of valproate) in ani-
mals with a distal sodium-hydrogen exchange accelerated by
chronic metabolic acidosis.
The renal utilization or production of critical metabolites is
presented in Table 4 and the apparent metabolic fluxes are
described in Figure 2. In the latter figure, the apparent meta-
bolic fluxes in the kidney are calculated as previously de-
scribed. The mass conversion through major metabolic path-
ways or release of metabolites can be estimated. This procedure
has the advantage of providing an indirect estimation of the
maximal amount of oxidation of the major metabolites ex-
tracted by the kidney and has been fully described in recent
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Table 3. Effect of valproate on urinary parameters
Normal dogs Acidotic dogs
control valproatecontrol vaiproate
Urine flow mI/mm 1.5 0.4 2.7 o.7 1.8 0.3 2.0 0.3
Urine pH 7.04 0.21 7.25 0.11 6.02 0.71 6.32 0.20
Urine PCO2 mm Hg 61.8 9.1 52.9 8.5 31.4 4.8" 39.3 7.0
Cco3/GFR %
CNa/GFR %
2.4 0.5
1.0 0.3
7.0 l.03.7 o7 1.3 0.2"3.1 0.7" 6.0 2.95.2 1.9
CK/GFR % 23.7 4.7 30.3 3.5 21.1 3.3 20.2 4.6
C1/GFR % 0.8 0.2 2.5 0.7a 3.6 1.0" 4.3 1.5
C lactate/GFR % 0.7 0.2 42.7 57 30.5 9.6
C pyruvate/GFR % 1.6 0.5 61.8 l1.0 4.5 2.1 96.1 17.8
GFR ml/min 34.4 8.0 29.2 6.7 21.9 3.4 14.4 2.4a
Renal blood flow mI/mm 253 25 185 58 157.5 37.4 82.0 12.3
Values are means SE (N = 6normal dogs and 8 acidotic dogs) and were calculated from the means of four (during the control period) and three
(during the experimental periods) 10-mm urinary collections. The values presented during valproate infusion were observed when a dose of 4 mgI
kg/mm was infused in both groups of dogs.
a Significant difference (P < 0.05) from the mean control value, the comparisons being made with the Student's 1-test for paired data.b Significant difference (P < 0.05) between the control values in normal and acidotic dogs, the comparisons being made with the Student's (-test
for unpaired data.
Table 4. Effect of vaiproate on renal utilization or production of metabolites
Norma1 dogs Acidotic dogs
control valproate control valproate
UNH4V
Renal vein ammonium
24 7
64 16
31 7
56 12
74 8b
84 21
110 l2
77 29
release
Total ammonium production 87 20 87 8 157 22" 187 35
Glutamine utilization —68 20 —65 6 —73 16 —108 22
Glutamate production 9 3 4 1 9 4 2 5
Alanine production 66 12 53 5 35 14 36 9
Lactate utilization/production —204 58 —21 3l —134 52 +17 4l
Pyruvate production 19 13 14 3 12 10 36 l5
Citrate utilization —18 5 —10 2 —12 5 —14 7
Values are means SE (N = 6normal dogs and 8 acidotic dogs) in micromoles per 100 ml GFR and were calculated from the means of four (dur-
ing the control period) and three (during the experimental periods) values. The values presented during valproate infusion were observed when a
dose of 4 mg/kg/mm was infused in both groups of dogs.
a Significant difference (P < 0.05) from the mean control value, the comparisons being made with the Student's (-test for paired data.b Significant difference (P < 0.05) between the control values in normal and acidotic dogs, the comparisons being made with the Student's 1-test
for unpaired data.
publications [26, 29, 30]. No significant changes in the renal
utilization or production of glutamate, alphaketoglutarate, as-
partate, alanine and citrate were induced by valproate in normal
dogs. In these dogs, the proximal glutamine extraction was
entirely accounted for by alanine and glutamate production. No
net flux through glutamate dehydrogenase (GLDH) was dem-
onstrated. At least 19 micromoles per 100 ml GFR of unmea-
sured amino acids were required to explain the mass balance
equation between measured amino acid utilization and the
production of ammonium (Table 4). A maximum conversion of
203 micromoles per 100 ml GFR of lactate and citrate into CO2
and glucose was demonstrated.
Vaiproate did not significantly change the extraction of
unidentified amino acids and the production of glutamate and
alanine, but a small net deaminating GLDH flux became appar-
ent. The renal lactate utilization was markedly reduced by
valproate and even changed into a net lactate production at the
highest dose of valproate (Fig. 3). The striking effect of these
changes was a marked fall in the apparent oxidation of carbon
skeletons of glutamine, lactate and citrate from 203 to 25
micromoles per 100 ml GFR. The maintenance of an unaffected
overall kidney function suggests that a new substrate now
supported the renal ATP turnover. Thus, this analysis demon-
strates a small but significant effect of valproate on proximal
tubule metabolism, and a major displacement of lactate oxida-
tion both in the proximal and distal nephron.
Even if the measured renal extraction of glutamine was not
significantly different in control and acidotic dogs, several
striking changes were induced by acidosis. A significant rise in
total ammonium production indicated an accelerated deamida-
tion/deamination of glutamine in the kidney, as reflected by the
significant increment in the deaminating GLDH flux. As previ-
ously described [29], other non-glutamine-dependent pathways
(55 micromoles per 100 ml GFR) contributed significantly to the
ammoniagenesis. An apparent oxidation of 163 micromoles per
100 ml GFR of carbon skeletons of glutamine, lactate and
citrate was observed.
When vaiproate was infused into acidotic dogs, the GLDH
flux rose markedly, whereas the utilization of unmeasured
amino acids decreased. Most of the carbon skeletons of
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(NH4 = 157) (NH4 = 187)
Fig. 2. Renal metabolism of glutamine and related metabolites in dogs
with normal acid-base equilibrium (upper panel) and with chronic
metabolic acidosis (lower panel). Means for glutamine, lactate and
citrate extracted and alanine and glutamate produced are given in Table
4 and are expressed as micromoles per 100 ml GFR. Numbers close to
each arrow represent the mean flux calculated from the measured
values for the reaction(s) represented by the arrow. The various
metabolites are shown to join the pyruvate (oxaloacetate) pool support-
ing both oxidation and gluconeogenesis. The total ammonium produc-
tion measured is indicated between parentheses. The presentation of
the data is fully described in references 29 and 30.
glutamine were now released from the kidney as alanine, lactate
and pyruvate. It must be pointed out that the renal lactate
utilization was now abolished and converted into a net lactate
production. The small amount of carbon skeletons now oxi-
dized was comparable to that observed in control dogs infused
with valproate. Again, a new source of NADH must support the
renal ATP turnover following vaiproate infusion. Thus the
overall effect of valproate in both control and acidotic dogs was
to increase the glutamine utilization through the GLDH path-
way (proximal effect) and to displace the majority of lactate
oxidation (mainly distal effect).
Metabolites profile of the renal cortex
In both normal and acidotic dogs, valproate strikingly re-
duced the renal cortical concentrations of glutamine, glutamate,
aiphaketoglutarate, citrate and, more modestly, those of mal-
ate, oxaloacetate, aspartate and alanine (Table 5). Furthermore,
because the lactate concentration was markedly increased and
that of pyruvate only modestly, a four-fold rise in the lactate!
pyruvate ratio (decreased cytosolic NAD!NADH ratio) was
observed following valproate infusion. The renal cortical lactate
concentration (6 mM), which was well above the arterial con-
centration (2 to 3 mM) despite the markedly decreased proximal
reabsorption of lactate, indicated an increased production
and!or a reduced utilization of lactate and pyruvate in the
kidney cortex. The significant fall in glutamine, glutamate and
alphaketoglutarate probably reflected their accelerated trans-
formation into lactate, as suggested on the metabolic flow chart
presented in Figure 2. In normal dogs, vaiproate infusion also
increased modestly the concentrations of phosphoenol-
pyruvate, 2-phosphoglycerate and 3-phosphoglycerate, where-
as it reduced that of glucose-6-phosphate. The concentrations
of acetoacetate, /3-hydroxybutyrate and fumarate remained
minimal and unchanged. Valproate decreased the renal ATP
concentration significantly only in dogs with normal acid-base
equilibrium and increased inorganic phosphate.
The increased lactate/pyruvate ratio observed in the blood
and the renal cortex of normal and acidotic dogs, in relation to
the amount of vaiproate infused, suggested a production of
NADH from valproate oxidation, which supported the renal
ATP turnover. It should be noted that these metabolite profiles
in the renal cortex mainly represented changes in proximal
tubules, a nephron segment which predominates in the super-
ficial tissue sample obtained for these measurements. For
practical reasons, it was impossible to obtain reliable freeze-
clamped tissue representative of the thick ascending limb (red
outer stripe of the inner medulla).
Transport studies
Figure 4A presents the uptake of lactate by brush border
membrane vesicles as a function of time. It can be seen that a
clear overshoot above the equilibrium situation (3600 seconds)
is observed after 90 to 120 seconds when Na and W gradients
(inside < outside) is established, but not when these gradients
are absent. The overshoot is progressively suppressed by
increasing concentrations of valproate (from 0.1 to 5 mM). In
contrast, 5 m acetate only modestly affects the lactate accu-
mulation process (not shown). When lactate uptake is examined
as a function of the vaiproate concentration (Fig. 4B), an
apparent K1 for valproate around 0.1 m is found, acetate and
cinnamate having little effect on lactate transport and accumu-
lation. We would conclude that these experiments demonstrate
a direct inhibitory effect of valproate on a sodium- (and proton-)
lactate contransport in dog brush border membrane.
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Fig. 3. Renal utilization of lactate observed before and during the
infusion of progressive quantities of valproate in dogs with normal
acid-base equilibrium. The renal utilization of lactate was changed into
a net production at the highest dosage of vaiproate.
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Table 5. Effect of valproate on metabolites profile of the renal cortex
Normal dogs Acidotic dogs
control valproate control valproate
Glutamine 0.71 0.04 0.22 0.03a 0.40 00&' 0.18 o.o3
Glutamate 5.09 0.20 2.17 0.22a 2.30 0.17" 1.05 0.08k
a-Ketoglutarate 0.064 0.005 0.025 0.004a 0.065 0.014 0.028 o.oo6
Malate 0.28 0.05 0.18 0.04 0.35 0.11 0.30 0.12
Oxaloacetate (calculated)
MDH-LDH 5.39 0.86 10.69 2.81
GOT 2.66 1.38 8.94 4.34
Aspartate 1.42 0.22 0.80 0.06 2.12 0.35 1.09 0.23a
Citrate 0.14 0.01 0.06 o.ola 0.59 0.28 0.33 0.l8
Lactate 0.52 0.06 3.66 0.89a 0.82 0.20 2.94 0.33a
Pyruvate 0.04 0.004 0.07 0.OP' 0.10 002b 0.11 0.02
Lactate/pyruvate 13 52 8 27
Alanine 1.05 0.02 0.94 0.09 1.16 0.14 0.70 o.o4
ATP 1.73 0.07 1.01 0.06 1.56 0.12 1.50 0.15
ADP 0.58 0.05 0.55 0.06 NM NM
AMP 0.12 0.02 0.16 0.02 NM NM
Inorganic phosphate 2.35 0.06 3.59 0.lOa 2.98 0.41 3.51 0.32
Calculated values
NAD/NADH (LDH) 693 172 1099 337
NAD/NADH (GLDH) 1.1 1.3 3.7 4.4
Values are means SE (N = 6 normal dogs and 8 acidotic dogs) before and at the end of valproate infusion. Results are expressed in micromoles
per gram wet weight except for oxaloacetate, expressed in nanomoles. Approximative values in m can be estimated by multiplying these numbers
by two. Abbreviations are: MDH, malate dehydrogenase; LDH, lactate dehydrogenase; GLDH, glutamate dehydrogenase; NM, not measured.
a Significant difference (P < 0.05) from the mean control value, the comparisons being made with the Student's t-test for paired data.b Significant difference (P < 0.05) between the control values in normal and acidotic dogs, the comparisons being made with the Student's 1-test
for unpaired data.
Discussion
Effects of vaiproate on renal tubular transport of lactate
and pyruvate
Vaiproate administration markedly reduced the renal reab-
sorption of lactate and pyruvate in a dose-dependent fashion.
This was not due to the observed increased concentration of
these substrates in the blood or in the renal cortex. Indeed, the
increment in lactate concentration in both tissues was modest,
while that of pyruvate remained virtually unchanged. Further-
more, a leak of lactate from the blood back to the lumen of the
nephron seems unlikely; usually the urinary lactate excretion
does not increase significantly when arterial lactate is increased
[31]. This lactaturia was not related to changes in blood or
tubular fluid pH, since the same effect was observed in normal
and chronically acidotic dogs.
In specific experiments with brush border membrane vesi-
des, we have demonstrated that valproate exerts a direct and
specific effect on the transporter for lactate present in this
membrane. This effect occurs at concentrations of valproate
below the plasma concentration (around 0.5 mM) induced by
oral vaiproate therapy in man [32]. This luminal transporter is
known to be competitively inhibited by different short-chain
fatty acids [33] and, as shown here, by valproate itself. A
specific inhibition of lactate (and pyruvate) reabsorption by
proximal tubules is therefore the most likely mechanism of the
observed lactaturia.
The absence of a significant effect on sodium, bicarbonate
and phosphate reabsorption further suggests that valproate
acted specifically on the lactate/pyruvate luminal transporter in
the brush border membrane. This is reminiscent of the inhibi-
tion by valproate of the pyruvate mitochondrial transporter
reported by Benavides et al [341. In view of the striking
amplitude of this effect, we suggest that urinary lactate might
possibly be used to evaluate the compliance of patients taking
this antiepileptic drug.
Metabolic effects of vaiproate
Abolishment of lactate and pyruvate oxidation. Valproate
induced a marked reduction in renal lactate utilization, and
even caused a net lactate production. This vvas accompanied by
an increased concentration of renal cortical lactate. The reduc-
tion in lactate utilization could not be due to the inhibited
reabsorption of lactate, as an increased cellular concentration
of this anion followed the higher arterial concentration and
cellular delivery through the basolateral membrane. At this site,
lactate is transported into the renal cell by an anion exchanger
which does not appear to be inhibited by valproate. The
reduced oxidation of lactate and pyruvate could theoretically
result from the following three mechanisms: 1) the observed
cytosolic redox shift driving pyruvate into lactate; 2) an effect of
valproate on the mitochondrial pyruvate transporter; 3) a de-
creased flux through mitochondrial pyruvate dehydrogenase
(PDH).
Because tissue pyruvate concentration did not decrease
significantly (mechanism 1), a redox-reduced fall in the pyru-
vate concentration below the Km of the mitochondrial trans-
porter cannot explain its reduced oxidation. A valproate-
induced inhibition of the mitochondrial transporter for pyruvate
may be one explanation (mechanism 2); however, this mecha-
nism alone would not account for this effect since the oxidation
of the pyruvate generated in the mitosol was also ieduced by
Fig. 4. A. Accumulation of'4C-L -lactate (40 M) into vesicles of brush border membranes as a function of time. In control situations as well as
in the presence of valproate, H+ and Na+ gradients were created across the vesicle membranes by manipulation of the intra-/extravesicular
medium composition: inside, pH 8.0 and 150 mi KCI, 0 m NaCl; outside, pH 6.0 and 150 mi NaCI, 0 mrs KCI. The "no gradient" situation
was obtained by incubating the vesicles in intra-vesicular medium. The early kinetics of lactate accumulation is presented in the insert. Symbols
are: (D) control, (•) 0.1 mi VPA, (A) 1.0 mi VPA, (•) 5.0 m VPA, (0)no gradient. B. Effect of progressive concentrations of vaiproate (•),
acetate (D) and a-cyano-hydroxy-cinnamate (A) on the accumulation of 14C-lactate measured at 30 seconds. The results are expressed as % of the
control (no effector) value.
valproate in vitro in proximal tubules [14J and thick ascending
limbs [35], suggesting PDH inhibition. This latter effect (mech-
anism 3) might result from a direct effect of valproate on the
PDH complex or from an increased phosphorylation of the
enzyme secondary to the oxidation of valproate itself. It is of
interest in this regard that the short-chain propionyl CoA and
isovaleryl CoA are known to inhibit PDH activity in the pig
kidney [36]. The production of vaiproyl CoA from vaiproate
[371 could have the same inhibitory effect.
The decreased pyruvate oxidation did not lead to alanine
synthesis because tissue pyruvate did not rise and because
glutamate concentration decreased. The inhibition of pyruvate
oxidation occurred in part in proximal tubules (refer to the
metabolites profiles) but must also occur in the thick ascending
limb and distal nephron. Indeed, in dogs with chronic metabolic
acidosis, most of the lactate extracted by the kidney is oxidized
by these distal segments of the nephron [28].
In view of the large reduction of renal lactate uptake, the
unchanged oxygen consumption and overall renal transport ob-
served in chronically acidotic dogs suggest a metabolic compe-
tition between valproate and lactate: the energy required for
reabsorption was maintained. This evidence, together with
similar observations obtained in vitro in renal tubules of prox-
imal or distal origin [141, suggest that the metabolism of
valproate itself may replace the oxidation of lactate/pyruvate. It
is known that valproate can support cerebral mitochondrial
respiration in vitro and serves as a source of NADH [38].
Accelerated conversion of glutamine into pyruvate. An ac-
celerated flux between glutamine and oxaloacetate was induced
by vaiproate as reflected by the marked reduction in the renal
cortical concentrations of glutamine, glutamate and alphaketo-
glutarate. However the concentrations of oxaloacetate and
malate did not rise secondarily, in sharp contrast with the
increment observed when these fluxes were accelerated by
acidosis [291. The simultaneous decrease of oxaloacetate for-
mation from pyruvate in vaiproate-treated dogs may explain
this discrepancy if tissue oxaloacetate reflects a simultaneous
production from glutamnine and pyruvate. Indeed pyruvate
carboxylase is an enzyme regulated in an allosteric fashion by
acetyl CoA [39]. A vaiproyl CoA production exceeding its
oxidation may decrease the tissue acetyl CoA 1401. A secondary
reduction in pyruvate carboxylase activity can thus be expected
and was suggested by the fall in the renal cortical concentra-
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tions of malate and citrate (octanoate being able to protect the
kidney against all these biochemical changes [371).
In vivo, only acidotic animals demonstrated a modest stimu-
lation of glutamine extraction and ammonia production. In
contrast, in vitro, valproate administration markedly increased
glutamine uptake and metabolism by both proximal tubules [14]
and thick ascending limbs [351 at pH 7.4. Both situations thus
contrast strikingly. This suggests that the in vivo situation
somehow protects the kidney against the ammoniagenic effect
of valproate. This may be related to the availability of endoge-
nous free fatty acids in vivo [41, 42]. The fact that vaiproate and
fatty acids have been reported to compete for the oxidation [43]
may contribute to this latter effect. Indeed, valproate inhibits
the oxidation of long-chain fatty acids probably through a
reduced carnitine availability [44, 45], due to valproyl carnitine
production, while octanoate reduces valproate oxidation.
Metabolism of vaiproate itself. Significant quantities of
valproate can be delivered to the kidney and be metabolized in
this organ [46, 47]. A significant renal metabolism of valproate
is suggested by the marked difference observed between the
total amount of valproate entering through the renal artery
(valproate in arterial renal plasma flow plus continuous infu-
sion) and the combined quantities measured in the renal vein
and urine, the urinary excretion of unchanged valproate being
minimal [481. Furthermore, the change in the tissue redox
potential, related to the infused load of valproate, also indicates
a local metabolism which probably occurred both in the prox-
imal tubules and in the distal nephron.
Indeed, sufficient /3-oxidation of valproate, a reaction occur-
ring in mitochondria [49], must have occurred to explain the
reduction of the tissue NAD/NADH ratio. Because vaiproate
induced a reduction and not an oxidation of the NAD/NADITI
ratio, valproate did not have in the kidney the uncoupling effect
described in brain and liver mitochondria [50]. Other tissues
than the kidney also metabolized valproate, since the arterial
lactate/pyruvate ratio exceeded that observed in the kidney
cortex.
Hyperammonemia. Despite the establishment of plasma con-
centrations of valproate much higher than the therapeutic
plasma concentration around 0.5 mrvi [51], a modest hyperam-
monemia was observed following valproate administration in
acidotic dogs only. Obviously, this effect did not result from a
shift of ammonium from urine to renal venous blood since no
urinary alkalinization, as observed with maleate [18, 52 and
4-pentenoate [53], occurred. Furthermore, the urinary excre-
tion of ammonium probably rose because of the increased
urinary excretion of lactate, acting as a poorly-reabsorbable
organic anion. The increased renal ammonium delivery to the
systemic blood resulting from chronic metabolic acidosis un-
masked a reduced capacity for hepatic detoxification of ammo-
nium following vaiproate administration, This suggests that
valproate-induced hyperammonemia may be worsened by met-
abolic acidosis increasing renal ammonium delivery to the
blood in presence of a valproate-induced reduced detoxification
into urea. The absence of a significant renal ammoniagenic
effect of valproate in the dog is in contrast to the data of Warter
et a!, who observed an increased release of ammonium into the
renal vein and hyperammonemia both in the rat [12] and man [9,
10, 42]. Species differences between man, the rat and the dog
could be responsible for this discrepancy.
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